Loading...
MEK/ERK inhibitors: proof-of-concept studies in lung fibrosis
There is no therapy for chronic fibroproliferative diseases, in spite of the fact that current health statistics suggest that these (which include cardiovascular disease, pulmonary fibrosis, diabetic nephropathy, liver cirrhosis and systemic sclerosis) have been estimated to cause approximately 45%...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer Netherlands
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3271198/ https://ncbi.nlm.nih.gov/pubmed/22131200 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12079-011-0156-9 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|